Hope Bancorp, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOPE research report →
Range $16 – $16
Price Chart
About the company
Hope Bancorp, Inc. , established in 2000 and headquartered in Los Angeles, California, functions as the parent entity for Bank of Hope. Through its subsidiary, Bank of Hope, it delivers a comprehensive suite of banking solutions to both individuals and small to medium-sized enterprises across the United States.
- CEO
- Kevin Sung Kim
- IPO
- 1998
- Employees
- 1,432
- HQ
- Los Angeles, CA, US
AI snapshot
Six angles, distilled from the data.
HOPE remains in a constructive multi-month uptrend, trading above its 200-day average and not far from its 52-week high. The setup is still recovery-like rather than stretched, with the stock holding well above the low end of its yearly range and showing a steadier trend than a high-beta regional bank.
Street sentiment is cautious-to-neutral, with a Hold consensus and a $16 target that sits above the current share price. Recent target work has edged higher, including a move to $16 from $15, but the broader rating mix still leans to Hold rather than a clear bullish call.
The next print carries a modestly favorable setup after three straight EPS beats, each by 3.8% to 4.5%. Analysts expect $0.30 EPS, above the prior quarter’s $0.27 run rate, so shareholders should watch whether loan growth and margin discipline can keep the beat streak alive.
Recent insider activity leans negative on discretionary trading, with four sales and no open-market buys. The May awards and other non-discretionary grants are noise; the signal is the cluster of sales by the chief risk officer and a director, which suggests limited near-term insider conviction.
Profitability is solid for a regional bank, with a 23.93% net margin, 34.24% operating margin, and 5.66% ROE. Growth is strong, with revenue up 71% year over year and EPS up 35.3%, while free cash flow of $177.6 million and net cash of $2.24 billion leave the balance sheet well covered.
HOPE screens cheaper than many quality regional banks at 13.41x earnings, while the consensus target implies room above the current multiple. Its appeal is balance-sheet strength and cash generation; the tradeoff is only moderate profitability versus stronger-return peers.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.75B
- P/E
- 13.67
- Fwd P/E
- 12.59
- PEG
- 0.07
- P/S
- 1.72
- P/B
- 0.76
- EV/EBITDA
- 10.17
- Div Yield
- 4.10%
- Gross Margin
- 53.91%
- Op Margin
- 16.07%
- Net Margin
- 12.58%
- ROE
- 5.61%
- ROIC
- 0.70%
Latest fiscal year · YoY change
- Revenue
- $967.79M-3.2%
- Gross Profit
- $470.36M+3.0%
- Op Income
- $80.73M
- Net Income
- $58.52M-41.3%
- EPS
- $0.46-44.6%
- OCF Growth
- +41.0%
- FCF Growth
- +41.7%
- 52W High
- $14.59
- 52W Low
- $9.80
- 50D MA
- $13.95
- 200D MA
- $12.61
- Beta
- 0.81
- RSI (14)
- 47
- Avg Volume
- 963.28K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Hope Bancorp reported a stronger second quarter with higher revenue, margin expansion, and improved profitability, while keeping full-year guidance unchanged and leaning on a pending Manubank acquisition to support future growth.· July 27, 2026
- Second-quarter revenue was $148 million, with diluted EPS of 26 cents and adjusted diluted EPS of 27 cents, up 17% sequentially and 40% year over year on an adjusted basis.
- Net interest margin expanded to 2.96%, up 6 basis points from the prior quarter and 27 basis points from a year ago, helped by higher loan yields and lower funding costs.
- Loans rose 2% sequentially to $15 billion and deposits increased 1% to $15.9 billion, with non-maturity deposits growing and time deposits declining as planned.
- Credit remained stable: net charge-offs were $9 million, criticized loans improved 19% year over year, and the allowance for credit losses was 1.03% of loans.
- Management kept 2026 guidance unchanged, still expecting about 20% end-of-period loan growth, 15% to 20% revenue growth, and 25% to 30% pre-provision net revenue growth, including a quarter of Manubank contribution in the fourth quarter.
Second-quarter 2026 revenue was $148 million. Reported diluted EPS was 26 cents, and diluted EPS excluding notable items was 27 cents, up from 23 cents in the first quarter and up 40% from 19 cents in the year-ago quarter. Pre-provision net revenue was $49 million excluding notable items, or $51 million including them, up 10% sequentially and 25% year over year. Net interest income was $129 million, up 4% sequentially and 10% year over year. Net interest margin was 2.96%, up 6 basis points sequentially and 27 basis points year over year. Non-interest income was $19 million, up 11% sequentially and 19% year over year excluding notable items. Non-interest expense was $98 million, or $96 million excluding merger-related costs, and the efficiency ratio excluding notable items improved to 65.2% from 66.9%. Gross loans were $15 billion, up 2% sequentially and 4% year over year, and deposits were $15.9 billion, up 1% sequentially. Credit metrics included criticized loans of $334 million, non-performing assets of $113 million, net charge-offs of $9 million, and an allowance for credit losses of $153 million. Full-year 2026 outlook remains essentially unchanged: end-of-period loan growth of approximately 20% including Manubank, revenue growth of 15% to 20%, and pre-provision net revenue growth of 25% to 30%, both excluding notable items and including a quarter of Manubank operations in the fourth quarter.
Kevin Kim said the quarter showed solid execution against key operating priorities, with stronger earnings, revenue growth, margin expansion, and improving profitability ratios. He emphasized that loan growth is strengthening, the deposit mix is improving, and the balance sheet remains positioned to support organic growth, capital returns, and the pending SMBC Manubank commercial banking acquisition. His tone was constructive and confident, but still framed around disciplined growth, pricing, structure, and credit standards rather than volume alone.
Juliana Imbilisca highlighted that net interest income rose to $129 million, net interest margin expanded to 2.96%, and non-interest income grew to $19 million, supported by SBA loan sales, customer-related fees, and securities gains. She said non-interest expense was $98 million, or $96 million excluding merger-related costs, and that the efficiency ratio improved to 65.2%, reflecting operating leverage. On credit, she noted criticized loans of $334 million, net charge-offs of $9 million, and an allowance for credit losses of $153 million with 1.03% coverage; on funding, she gave a June deposit spot rate of 2.58% and an interest-bearing deposit rate of 3.32%, while saying the cost of incremental competitive deposits is running about 350 to 380.
Analysts focused on deposit costs, time deposit mix, the SBA gain-on-sale outlook, and the timing and modeling impact of the pending Manubank transaction. Management said the NIM should still rise by a few basis points each quarter for the rest of the year, though not as much as in the first-to-second-quarter move, and that deposit pricing remains competitive. They also said the 2026 SBA gain-on-sale outlook is about $16 million to $17 million, the Manubank deal is still expected to close in the second half of 2026, and the guide assumes roughly one quarter of Manubank contribution. In response to deposit mix questions, management said it wants to reduce CD reliance over time but does not have a specific target and expects diversification from Territorial and Manubank to help.
The call pointed to broad operating momentum: higher revenue, better margins, stronger EPS, and positive operating leverage, all while loans and deposits still grew. Management sounded confident that the Manubank acquisition will add quality loans and deposits, broaden multinational capabilities, and support long-term growth and returns. Credit also looked manageable, with criticized loans down sharply year over year and the allowance coverage still above 1% of loans.
Management repeatedly acknowledged that deposit pricing remains competitive, and that reducing reliance on CDs will take time. The Manubank deal still depends on regulatory approvals and timing remains uncertain, even though the company expects a second-half close. SBA gain-on-sale income may normalize from the quarter’s stronger pace, and management said future NIM expansion should continue but be smaller than the recent step-up.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.1%
- Shares Outstanding
- 127.84M
- Float Shares
- 124.11M
of shares held by institutions
252 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HOPE, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 18.47M | ▲ 228.25K |
| Vanguard Group Inc | 13.87M | ▼ 13.34K |
| Wellington Management Group Llp | 11.44M | ▲ 1.45M |
| State Street Corp | 7.58M | ▲ 248.51K |
| Vanguard Portfolio Management LLC | 7.57M | ▲ 73.72K |
| Dimensional Fund Advisors LP | 7.49M | ▲ 117.85K |
| Holdco Asset Management, LP | 6.26M | 0 |
| Fuller & Thaler Asset Management, Inc. | 5.71M | ▼ 204.83K |
| Vanguard Capital Management LLC | 5.53M | ▲ 22.36K |
| Macquarie Management Holdings, Inc. | 4.24M | ▼ 194.08K |
| American Century Companies Inc | 3.61M | ▲ 343.71K |
| Geode Capital Management, LLC | 3.41M | ▲ 175.32K |
Held by 363 ETFs
Biggest fund positions in HOPE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Stenger Thomas | sell | 1,650 |
| Aug 3, 26 | HA DAISY Y | sell | 26,995 |
| Jun 8, 26 | Stenger Thomas | sell | 1,500 |
| May 21, 26 | Byun Donald | other | 5,060 |
| May 21, 26 | Lee Rachel H. | other | 4,337 |
| May 21, 26 | Doo Jinho | other | 5,060 |
| May 21, 26 | Nakajima Takaaki | other | 4,337 |
| May 21, 26 | Kim Joon Kyung | other | 5,783 |
| May 21, 26 | Zuehls Dale S. | other | 7,373 |
| May 21, 26 | HA DAISY Y | other | 4,337 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HOPE coverage
Recent articles, reports, and earnings notes.

Hope Bancorp (HOPE): Recovery Story With CRE Risk
Hope Bancorp is showing improving earnings power as deposit costs fall and acquisitions add scale, but commercial real estate exposure and integration risk keep the stock at Hold. Analysts see a sharp EPS rebound ahead, yet the shares still trade below book value with execution still unproven.

Hope Bancorp, Inc. (HOPE) gains on deep earnings beat
Hope Bancorp, Inc. (HOPE) gains after a modest Q2 earnings beat, but the real story is deeper: margin expansion, stronger operating leverage, and improving fee income. This analysis breaks down what drove the move, how sustainable the gains may be, and why guidance matters.

Hope Bancorp, Inc. (HOPE) gains on earnings beats
Hope Bancorp, Inc. (HOPE) gains 2.7% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.
Want a deeper read on HOPE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Hope Bancorp (NASDAQ:HOPE) Share Price Breaks Above Two Hundred Day Moving Average – Time to Sell?
defenseworld.net · Oct 6
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
globenewswire.com · Oct 5
Bank of Hope Completes Acquisition of the Commercial Banking Unit of SMBC MANUBANK
businesswire.com · Oct 1
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
globenewswire.com · Sep 17
Bank of Hope Receives Regulatory Approvals to Acquire the Commercial Banking Unit of SMBC MANUBANK
businesswire.com · Sep 2
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
gurufocus.com · Aug 6
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy
globenewswire.com · Jul 29
Hope Bancorp's Great Quarter Doesn't Mean An Upgrade Is Justified
seekingalpha.com · Jul 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed October 3, 2026 · Live quote · Not investment advice